Michael L. Meyers - 02 Feb 2022 Form 4 Insider Report for Syndax Pharmaceuticals Inc (SNDX)

Role: SVP, Chief Medical Officer
Signature: /s/ Michael A. Metzger, Attorney-in-Fact
Issuer symbol: SNDX
Transactions as of: 02 Feb 2022
Net transactions value: +$295,193
Form type: 4
Filing time: 03 Feb 2022, 16:31:53 UTC
Previous filing: 03 Jan 2022
Next filing: 06 Oct 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SNDX	Common Stock	Other	$21,236	+1,714	+7.9%	$12.39	23,280	31 Jan 2022	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	SNDX	Stock Options (Right to buy)	Award	$273,956	+17,350		$15.79	17,350	02 Feb 2022	Common Stock	17,350	$15.79	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,715 shares by the Reporting Person on 1/31/22 pursuant to the Issuer's Employee Stock Purchase Plan.
F2	1/23rd of the shares subject to the option shall vest monthly over a two-year period.